Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-11-01 5:01 pm Sale | 2022-10-20 | 13D | AVEO Pharmaceuticals, Inc. AVEO | Growth Equity Opportunities Fund IV, LLC | 0 0.000% | -5,424,009 (Position Closed) | Filing History |
| 2022-10-20 4:05 pm Sale | 2022-10-16 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Orin Hirschman | 975,993 2.800% | -1,735,377 (-64.00%) | Filing History |
| 2022-02-11 3:32 pm Purchase | 2021-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Orin Hirschman | 2,711,370 7.900% | 669,559 (+32.79%) | Filing History |
| 2021-09-14 6:11 pm Purchase | 2021-09-03 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Orin Hirschman | 2,041,811 5.940% | 2,041,811 (New Position) | Filing History |
| 2021-04-09 6:02 pm Purchase | 2021-03-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | BlackRock Inc. BLK | 1,605,160 4.800% | 36,805 (+2.35%) | Filing History |
| 2021-02-16 3:07 pm Sale | 2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Cormorant Asset Management LP | 0 0.000% | -1,350,000 (Position Closed) | Filing History |
| 2021-02-12 12:39 pm Sale | 2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | James E. Flynn | 0 0.000% | -1,574,000 (Position Closed) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | AVEO Pharmaceuticals, Inc. AVEO | BlackRock Inc. BLK | 1,568,355 5.400% | 1,568,355 (New Position) | Filing History |
| 2020-06-29 5:22 pm Unchanged | 2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Cormorant Asset Management LP | 1,350,000 5.230% | 0 (Unchanged) | Filing History |
| 2020-06-29 5:22 pm Purchase | 2020-06-17 | 13G | AVEO Pharmaceuticals, Inc. AVEO | Cormorant Asset Management LP | 1,350,000 5.230% | 1,350,000 (New Position) | Filing History |
| 2020-06-24 5:03 pm Purchase | 2020-06-19 | 13D | AVEO Pharmaceuticals, Inc. AVEO | Growth Equity Opportunities Fund IV, LLC | 5,424,009 20.800% | 1,428,570 (+35.76%) | Filing History |
| 2020-06-19 12:10 pm Purchase | 2020-06-19 | 13G | AVEO Pharmaceuticals, Inc. AVEO | James E. Flynn | 1,574,000 6.090% | 1,574,000 (New Position) | Filing History |